Clinical trials: Percutaneous Coronary Intervention Patients
STEMI
CHA2DS2-VASc Score as a Predictor of Thrombus Burden and Clinical Outcomes in Patients Undergoing PPCI.
Aim of the work is to evaluate the use CHA2DS2-VASc score in predicting no-reflow phenomenon and its impact on short term primary percutaneous coronary intervention outcomes (in-hospital mortality) and long term (6 months)…
- Trial name
- NCT04565808
- Testing
- primary percutaneous coronary intervention
- Volunteers
- 184 people
- Sponsor
- Assiut University
ST Elevation Myocardial Infarction
Evolocumab in STEMI
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary…
- Trial name
- EVO-STEMI (NCT06081803)
- Testing
- Repatha®
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Sejong General Hospital
Comorbidities and Coexisting Conditions, Ethics
eCardiacRehab - a Hybrid Patient-Centered eHealth Programme
The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy…
- Conditions
- Comorbidities and Coexisting Conditions, Ethics, Continuity of Patient Care, Older Adults (65 Years and Older)
- Trial name
- eCardiacRehab (NCT07590635)
- Testing
- eCardiacRehab
- Where
- Norway
- Volunteers
- 1,000 people
- Sponsor
- Haukeland University Hospital
Coronary Heart Disease
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction
To evaluate whether nicorandil as an adjunctive therapy for acute myocardial infarction (AMI) reduces reperfusion injury.
- Trial name
- NCT02435797
- Testing
- Nicorandil, normal saline
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuzhou Central Hospital
Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that…
- Conditions
- Percutaneous Coronary Intervention, Dual Antiplatelet Therapy, Aspirin, Clopidogrel
- Trial name
- TRIAGE (NCT01582217)
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Unstable Angina Pectoris, Coronary Stent Implantation
Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation
The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese unstable angina patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticagrelor (45 mg twice-daily)…
- Trial name
- NCT03620760
- Testing
- Ticagrelor 90 mg, Ticagrelor 45 mg, Aspirin
- Where
- China
- Volunteers
- 2,036 people
- Sponsor
- Xiaofan Wu
Coronary Artery Disease, Percutaneous Coronary Intervention
The xDAPT External Validation Study
Dual antiplatelet therapy (DAPT) is routinely recommended after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation to prevent thrombotic complications.
- Trial name
- xDAPT (NCT06736626)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Coronary Syndrome
Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention
High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent…
- Trial name
- PRAISE-HPR (NCT01609647)
- Testing
- Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Dong-A University
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Heparin-Induced Thrombocytopenia, Thrombosis
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome…
- Trial name
- NCT00043940
- Testing
- bivalirudin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Medicines Company
Percutaneous Coronary Intervention
A Nurse-Led Program to Improve Patient Health Promotion Behaviors Among Elderly Patients After PCI
The goal of this study is to develop and evaluate a nurse-led intervention program based on the Information-Motivation-Behavioral Skills (IMB) model to improve health-promoting behaviors and quality of life in elderly patients…
- Trial name
- NCT07683143
- Testing
- Nurse-led intervention
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Henan University
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Myocardial Infarction, Coronary Artery Disease
TIMELY: a Patient-centred Lifestyle Program for Patients With Coronary Artery Disease
Study design: A randomized controlled trial will be used, where patients will be randomized (1:1) to either the control group receiving usual care or the intervention group in which patients will receive usual care in combination…
- Trial name
- TIMELY (NCT05955625)
- Testing
- TIMELY
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 358 people
- Sponsor
- Tilburg University
Atrial Fibrillation, Acute Coronary Syndrome
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
Currently, there is minimal data on the combination of rivaroxaban and ticagrelor in patients with atrial fibrillation (AF) managed with percutaneous coronary intervention (PCI).
- Trial name
- CAPITAL PCI AF (NCT03331484)
- Testing
- Ticagrelor, Rivaroxaban
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Percutaneous Coronary Intervention, High Bleeding Risk
Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking. Methods.
- Conditions
- Percutaneous Coronary Intervention, High Bleeding Risk, Acute Coronary Syndromes, Anticoagulant Therapy
- Trial name
- BRIGHT-HBR (NCT07383155)
- Testing
- Anticoagulant Therapy
- Volunteers
- 5,270 people
- Sponsor
- Shenyang Northern Hospital
Percutaneous Coronary Intervention (PCI), Acute Myocardial Infarction
Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease
Endothelial dysfunction is one of the aetiological factors in ischaemic heart disease (IHD). Aerobic exercise is effective in improving endothelial function, as measured by flow-mediated dilation (FMD), in patients with IHD.
- Conditions
- Percutaneous Coronary Intervention (PCI), Acute Myocardial Infarction, Angina (Stable), Unstable Angina Pectoris
- Trial name
- ENDO-R (NCT06788275)
- Testing
- Aerobic exercise (MIT), Aerobic exercise (Short HIIT), Aerobic exercise (Long HIIT)
- Where
- 2 sites in Spain
- Volunteers
- 132 people
- Sponsor
- Instituto de Investigación Sanitaria y Biomédica de Alicante
ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban.
- Trial name
- NCT07195812
- Testing
- Dual Antiplatelet (DAPT) Therapy, Rivaroxaban
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Coronary Syndrome, Myocardial Infarction
Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are…
- Trial name
- NCT01623700
- Where
- Sweden
- Volunteers
- 78,000 people
- Sponsor
- Uppsala University
Myocardial Ischemia, CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Influences Outcome of Coronary Artery Stenting
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
- Trial name
- GENIUS (NCT02707445)
- Testing
- Clopidogrel
- Volunteers
- 5,000 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease, Diabetes
Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES
The objective of the study is to compare angiographic and clinical performance of Abluminus DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.
- Trial name
- NCT03399994
- Testing
- device implantation during coronary angioplasty
- Where
- 6 sites in Italy
- Volunteers
- 137 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS